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Prostate cancer is the most common cancer in elder men (Coffey,
1993); the majority of whom with advanced disease develop bone
metastases if they live long enough (Hortobagyi, 1991; Vinholes
et al, 1996; Rubens, 1998). 
Once bone metastases become clinically evident, the disease
becomes almost invariably refractory to hormones and only few
palliative means are available to combat cancer progression and
the occurrence of serious complications related to metastatic bone
involvement (Hortobagyi, 1991; Francini et al, 1993; Rubens,
1998). Active specific immunotherapy and tumour-associated
antigens (TAA)-specific adoptive immunotherapy are currently
being investigated throughout the world as novel strategies for
treating prostate cancer. In these cases it is generally accepted that
a T lymphocyte response to TAA is indispensable for obtaining an
efficient and prolonged tumour rejection in vivo (Marincola, 1994;
Restifo and Sznol, 1997, pp 3023–3038). Tumour-infiltrating
lymphocytes (TIL) are the final result of the long battle occurring
between the host immune reaction and the continued cancer cell
development and growth (Vose and Moore, 1985; Topalian et al,
1987; Topalian and Rosenberg, 1989; Whiteside, 1991; Rosenberg
et al, 1994; Whiteside and Parmiani, 1994; Pierce et al, 1995), and
the preclinical data concerning in vitro TIL activation against the
autologous tumour cells collected over the last 10 years has
encouraged a large number of clinical reinfusion trials using TIL
plus interleukin 2 (IL-2) (Topalian et al, 1987). For many different
reasons, these studies led to very conflicting results in terms of
clinical effectiveness and reproducibility (Rosenberg et al, 1994;
Pierce et al, 1995; Restifo and Sznol, 1997). 
The greater knowledge regarding the human cell-mediated
immune system acquired over the last few years has made it
possible to improve the anti-tumour potential of these effector
cells. It is now known that tumour cells can be recognized and
killed by activated lymphocyte effectors but cannot start a demon-
strable de novo CTL immune reaction (Melero et al, 1997), which
requires professional antigen-presenting cells (APC) such as
dendritic cells (DC), that are capable of uptaking, processing and
presenting to the CTL precursors antigen proteins released by
tumour cells (Grabbe et al, 1995; Romani et al, 1996; Bell et al,
1999). Furthermore, it has also been discovered that T lympho-
cytes recognize tumour as well as viral protein antigens as small
peptides (peptide epitopes) which are products of intracellular
degradation of antigen protein, bound to major histocompatibility
complex (MHC) molecules on target cells (Melero et al, 1997).
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Summary Bone metastases are one of the most common events in patients with prostate carcinoma. PTH-rP, a protein produced by prostate
carcinoma and other epithelial cancers, is a key agent for the development of bone metastases. A PTH-rP-derived peptide, designated PTR-
4 was identified, which is capable to bind HLA-A2.1 molecules and to generate PTH-rP-specific cytotoxic T cell (CTL) lines from healthy HLA-
A2.1+ individual peripheral-blood-mononuclear-cells (PBMC). In this model, we investigated the in vitro possibility of generating an efficient
PTH-rP specific CTL response by cyclical stimulations with IL-2 and PTR-4 peptide-pulsed autologous dendritic cells (DC), of HLA-A2.1+
tumour infiltrating lymphocytes (TIL) derived from a patient with metastatic prostate carcinoma. A T cell line generated in this way (called TM-
PTR-4) had a CD3+, CD5+, CD4–, CD8+, CD45Ro+, CD56– immunophenotype and a HLA-A2.1 restricted cytotoxic activity to PTR-4-peptide
pulsed CIR-A2 (HLA-A2.1+) target cells, PTH-rP+/HLA-A2.1+ CIR-A2 transfected with PTH-rP gene, prostate carcinoma LNCaP cells, and
autologous metastatic prostate cancer cells (M-CaP). These lymphocytes were not cytotoxic to HLA-A2.1+ targets not producing PTH-rP, such
as peptide-unpulsed CIR-A2 and colon carcinoma SW-1463, cell lines. Our results provide evidence that PTR-4 peptide-pulsed autologous
DC may break the tolerance of human TIL against the autologous tumour by inducing a PTH-rP-specific CTL immune reaction. In conclusion
PTR-4 peptide-pulsed autologous DC may be a promising approach for vaccine-therapy and antigen-specific CTL adoptive immunotherapy
of hormone-resistant prostrate cancer. © 2001 Cancer Research Campaign  http://www.bjcancer.com
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Epitope peptide binding to specific HLA isotypes is determined by
definite consensus motifs present in the amino acid sequence of
antigen peptides (Cerundolo et al, 1990). 
A number of these sequences have been described for the most
common human leukocyte antigen (HLA) isotypes, and CTL
epitope peptides with HLA-A2.1 binding motifs capable of gener-
ating antigen-specific CTL lines with anti-tumour activity have
been derived from most common TAA (Jung and Schluesener,
1991; Van der Bruggen et al, 1991; Fenton et al, 1993; Houbiers
et al, 1993; Tsang et al, 1994, 1995; Abrams et al, 1995; Correale
et al, 1997; Tjoa et al, 1998; Francini et al, 2001). Recent in vitro
and in vivo findings also demonstrated the possibility to induce a
CTL immune response against TAAs produced by prostate cancer,
such as prostate-specific antigen (PSA) (Correale et al, 1997),
parathyroid hormone-related protein (PTH-rP) (Francini et al,
2000), and prostate-specific membrane antigen (PSMA) (Tjoa et
al, 1998). Various studies have evaluated the possibility of
inducing a TAA-specific CTL response from peripheral blood
mononuclear cells (PBMC), and identified a number of new 
TAA and peptide epitopes to be used in clinical trials of active
specific immunotherapy. In this contest, we have recently identi-
fied and characterized 4 HLA-A2.1 binding epitope peptides 
from PTH-rP, a 177 amino acid protein that is produced by 
90% or prostate carcinoma cells and is a key agent for the survival
and growth of prostate cancer cells in the bone tissue (Guise,
1997). 
These peptides were designated PTR-1, -2, -3 and -4, and were
used to generate an HLA-A2.1 restricted, PTH-rP-specific CTL
response leading to the generation from PBMC of healthy HLA-
A2.1+ individuals, of PTH-rP-specific CTL lines with antitumour
activity in vitro (Francini et al, 2001). 
Although CTL lines have been established for the most
common prostate cancer-associated antigens very few studies have
been conversely designed to investigate the possibility to induce
an antigen peptide-specific CTL response in TIL derived from
patients with non-immunogenic tumours such as prostate carci-
noma; furthermore, no clear demonstration that an antigen-
specific CTL response with antitumour activity may be generated
from human TIL isolated from prostate cancer metastatic tissue
has never been provided. 
In a recent clinical trial we observed that the sequential admin-
istration of granulocyte-monocyte colony stimulating factor
(GM-CSF) (150 µ g day–1 s.c. for 5 days) followed by very low
dose s.c. human recombinant interleukin-2 (IL-2) in patients
with very advanced cancers led to a significant increase in and
activation of peripheral DC (Correale et al, 2001). Before being
enrolled in the clinical trial, one of these patients with advanced
prostate carcinoma underwent a diagnostic bone biopsy from
which cancer cells and TIL could be isolated and cultured in
vitro; PBMC isolated from this patient before, during and after
cytokine administration were also isolated and made available
for immunological studies. 
Aim of the present in vitro study was to investigate the possi-
bility of generating an efficient human CTL response to PTH-rP
by stimulating TIL derived from prostate cancer bone metastases
with PTH-rP peptide-pulsed autologous DC isolated after GM-
CSF and IL-2 treatment. The rationale of this study was based on
the hypothesis that TAA epitope peptide stimulation in the pres-
ence of activated autologous DC may restore the antigen-specific
cytolytic activity of these TIL against the autologous tumour cells
expressing the specific target antigen. 
MATERIAL AND METHODS 
Cell cultures 
The prostate carcinoma LNCaP and the colon carcinoma SW1463
cell lines were purchased from American Type Culture Collection
(Rockville, MD, USA). The cultures were mycoplasma free and
were maintained in complete medium (Dulbecco’s modified Eagle
medium) (Life Technologies Inc (Gibco BRL), Grand Island, NY)
supplemented with 10% heat inactivated fetal bovine serum
(FBS), 2 mM glutamine, 100 U ml–1 penicillin, and 100 µ g ml–1
streptomycin (Life Technologies Inc). The CIR-A2 cell line was
provided by Dr Jeffry Schlom (Experimental Oncology Section,
National Cancer Institute, National Institute of Health, Bethesda
MD, USA) and maintained in Iscove’s modified Dulbecco’s
complete medium (IMDM). 
Peptide synthesis 
Synthesis of PTR-4 peptides (amino acid sequence: TSTTSLELD)
was performed on a solid phase automatic peptide synthe-
sizer (model syto, MultiSyntech, Witten, D) using the
Fluorenylmethoxycarbonyl (Fmoc)/Diisopropylcarbodiimide
(DIC)/1-Hydroxybenzotriazole (HOBT) strategy. Peptides were
cleaved from the resins and defracted by treatment with trifluo-
roacetic acid containing ethandiethiol, water trisbuthyl silone and
anisole (93/2.5/2/1.5/1). The crude peptides were purified by
HPLC using a Vydac C18 column (25 cm × 1 cm, 10 µ m). The
products dissolved in bi-distilled water, sterile filtered and frozen
at –70˚C at a concentration of 2 mg ml–1. The purity of the peptides
was more than 90% as analysed by high-performance liquid chro-
matography (HPLC). The CAP-1 control peptide was kindly
donated by Dr J Schlom. 
TIL cell culture and expansion 
Tissue obtained from biopsy samples of metastatic bone were
mechanically fragmented and seeded in T25 (Corning, Costar
Milano, Italia) dissolved in AIM-V medium supplemented with
5% pooled human heat-inactivated AB serum (Valley Biomedical,
Winchester, VA), 2 mM glutamine, 100 U ml–1 penicillin, and 100
µ g ml–1 of streptomycin (Flow, Irvine, UK), and containing 6000
IU ml–1 recombinant IL-2 (Cetus Corp, Emeryville, CA, USA).
The cells were incubated at 37˚C and 5% CO2 for 96 hours. The
mononucleate cells were subsequently, separated using density
gradients. The cell suspension obtained was cultured at the
concentration of 1 × 106 cell ml–1 in 24-multiwell plates (Corning,
Costar Milano, Italia) in the same IL-2-containing medium. One
week later, the cells were evaluated for T cell immune phenotype
and stimulated with peptide-pulsed autologous DC as described
above for PTH-rP peptide-specific CTL lines. 
Generation of DC and T cell lines 
PBMC were isolated before, during and after treatment with GM-
CSF and IL-2 from heparinized blood taken from a HLA-A2+ male
donor affected by advanced prostate carcinoma using a lympho-
cyte separation medium gradient (Celbio Biotecnologie SRL,
Milano, Italia) as previously described (Boyum et al, 1968). 
PBMC for DC enrichment (107 cell ml–1) were seeded in T75
flasks in a 10 ml volume of complete medium (RPMI-1640) with
10% heat inactivated FBS. After 4 hours’ incubation at 37˚C in 5%1724 P Correale et al 
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CO2, the non-adherent cells were removed and adherent cells were
maintained for 7 days in complete medium (RPMI-1640 with 10%
heat inactivated FBS, 2 mM glutamine, 100 U ml–1 penicillin, and
100  µ gm l –1 streptomycin) containing 50 ng ml–1 of GM-CSF
(Molgramostim, kindly furnished by the Shering Plough, SPA,
Milano, Italia) and 0.5 ng ml–1 of IL-4 (purchased from the R and
D systems, Minneapolis, MN, USA). The medium containing GM-
CSF and IL-4 was replaced every 48 hours. After 7 days of culture
the DC phenotype cells was evaluated by means of direct immuno-
fluorescence flow cytometry. In order to estimate the DC enrich-
ment before CTL stimulation, the cultures were examined for the
expression of CD1a, HLA-I, HLA-DR, CD11c, CD80, CD83 and
CD86, which are markers known to be highly expressed by DC
and involved in T cell costimulation and activation (Grabbe et al,
1995; Romani et al, 1995; Bell et al, 1999). 
The TIL for CTL primary cultures, were washed and then resus-
pended in AIM-V medium (Life Technologies, SRL, Milano,
Italia) supplemented with 5% pooled human heat-inactivated AB
serum (Valley Biomedical, Winchester, VA), 2 mM glutamine, 100
Um l –1 penicillin, and 100 µ gm –1 of streptomycin (Gibco). The
cells (2 × 105) in a volume of 100 µ l of complete medium were
added to each well of a 96-well flat-bottom assay plate (Corning,
Costar Milano, Italia). 
Irradiated autologous DC were pulsed with PTR-4 peptides
(25 µ gm l –1) and added to the lymphocyte cultures at the final ratio
of 1:5. DC cultures were irradiated prior TIL or PBMC in vitro
stimulation, in order to prevent the possibility that contaminating
NK or T cells could proliferate in presence of TIL and cytokines,
affecting the clonal expansion of PTH-rP peptide-specific T cell
clones.
Cultures were incubated for 5 days at 37˚C in a humidified
atmosphere containing 5% CO2, and then provided with human
recombinant IL-2 (20 U ml–1) for 11 days, with the IL-2-containing
medium being replenished every 3 days. The incubation time of
5 days with peptide-pulsed DC plus 10 days with IL-2 constitutes
one in vitro stimulation cycle (IVS). The T cell cultures were
re-stimulated with PTH-rP peptide (25 µ gm l –1) pulsed autologous
DC on day 16. Irradiated (5000 rads) autologous DC were added in
a volume of 100 µ l of complete medium (AIM-V) and used as
antigen-presenting cells. 
The progenitor TIL cultures were maintained in AIM-V
medium supplemented with 5% pooled human heat inactivated AB
serum, 2 mM glutamine, 100 U ml–1 penicillin, and 100 µ gm l –1 of
streptomycin, and containing 20 IU ml–1 of IL-2. The TIL cultures
were restimulated every 15 days with autologous irradiated DC
cells plus autologous irradiated prostate cancer cells in a 5:1 ratio. 
T cell lines 
PBMC, for CTL primary cultures, were suspended in AIM-V
medium (Life Technologies Inc) supplemented with 5% pooled
human heat inactivated AB serum (Valley Biomedical, Winchester,
VA), 2 mM L-glutamine, 100 U ml–1 penicillin/streptomycin
(Gibco). 2 × 105 cells, in a volume of 100 µ l, were seeded into each
well of a 96-well microplate (Corning, Costar Corp, Cambridge,
MA). 
Autologous DC were first irradiated (5000 R) and pulsed with
25 µ gm l –1 of PTR-4 and then added to the lymphocyte cultures to
the final ratio of 1:5. One in vitro stimulation cycle (IVS) was
represented by a 5-day period of cell incubation with antigen-
loaded DC plus a 10-day period of cell stimulation with 50 IU of
IL-2 (Cetus corp). Fresh complete medium containing cytokines
was replaced every 48 hours. On the 16th day, T cell cultures were
re-stimulated with autologous irradiated DC pulsed with PTR-4
used as-antigen presenting cells. 
Culture and expansion of prostate cancer cell derived
from bone metastases 
The tissue obtained from metastatic bone samples, taken by bone
biopsy, were mechanically fragmented and seeded in T25 flasks
(Corning, Costar Milano, Italia) in RPMI medium supplemented
with 5% pooled human heat inactivated AB serum, 2 mM
glutamine, 100 U ml–1 penicillin, and 100 µ gm l –1 of strepto-
mycin, and containing 100 IU of human recombinant Insulin
(Sigma-Aldrich, SRL, Milano, Italia) and 10–8 M androstenedyone
(Sigma-Aldrich, SRL, Milano, Italia). The cells were incubated at
37˚C and 5% CO2 for 6 weeks with the medium being replenished
every week. Adherent cells with epithelial cell features appeared
evident after 2 weeks of culture. After 6 weeks cells were studied
by a pathologist and immunohistochemically analysed for the
expression of cytokeratines and PSA. 
Immunohistochemistry 
The slides containing the cultured cells, were fixed in cold acetone
for 10 minutes, and were incubated with anti-human PSA mouse
monoclonal antibody (Immunotech, Marseille, France) diluted 1:500
in TBS; then the reaction was revealed using streptovidin–biotin
complex. Slides were weakly counterstained with Harris’ haematox-
ilin, mounted with aqueous mounting medium and examined under
a light microscope. Negative controls were obtained for each case
by replacing the specific antibody with non-immune serum
immunoglobulin at the same concentration as the primary antibody.
Immune reactivity was assessed using routine light microscopy. 
Target cell transfection with PTH-rP plasmid 
The GC90 plasmid engineered to express PTH-rP has been previ-
ously described by our group (Correale et al, 2001b). The pcDNA3
expression vector (In Vitrogen) was utilised to obtain the recombi-
nant plasmid GC90. Plasmid DNA was purified by Qiagen Endo
Free plasmid kit (QIAGEN) as described by the manufacturer. 
Approximately 105 CIR-A2 target cells were grown in 6-well
microplates at 37˚C transfected with 1 µ g of plasmid DNA using the
Effectene Transfection reagent (QIAGEN) as described by the manu-
facturer. After 2 days, PTH-rP antigen expression was analysed by
evaluating the presence of the specific mRNA by RT-PCR and by
immunofluorescence. Briefly, the cells were washed twice with PBS,
fixed with cold methanol/acetone and treated with a rabbit anti-PTH-
rP serum (Calbiochem) followed by FITC-conjugated goat-anti-
rabbit IgG (1/100) (DBA). The coverslips were mounted on slides
and examined using a Diaplan microscope (Leitz).
Cytotoxic assays 
Various target cells were labelled with 100 µ Ci of Na2Cr51O4
(Amersham, Aylesbury, UK) for 60 minutes at room temperature.
Target cells (0.5 × 104) in 100 µ l of complete medium (see below)
were added to each of 96 wells in T-flat bottom assay plates
(Corning Costar Italia, Milano). The labelled targets were incu-
bated at 37˚C in 5% CO2 before adding effector cells. The T cells
were then suspended in 100 µ l of AIM-V medium and added to the
target cells. The plates were incubated at 37˚C for 18 hours. The
supernatants were harvested for γ -counting using harvester framesTIL-derived PTH-rP-specific T lymphocytes 1725
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(Skatron, Inc, Sterling, VA, USA). The determinations were
carried out in triplicate and the standard deviations were calcu-
lated. All of the experiments were repeated at least 3 times. 
Specific lysis was calculated as follows:
Spontaneous release was determined from wells to which 100 µ l
of complete medium had been added instead of effector cells; total
releasable radioactivity was measured after treating the targets
with 2.5% Triton X-100. 
Blocking experiments 
For HLA blocking experiments, UPC-10 control mAbs
(Cappel/Organon Technique Corp, West Chester, PA, USA) or anti-
HLA-A2 mAbs (A2.69, #189HA-1; One Lambda Inc, Canoga
Park, CA, USA) at the dilution of 1:100 dilution were added to the
labelled target cells (M-CaP and LNCaP cells) and incubated for 1
hour before the cytotoxic assay. 
Flow cytometry 
Single colour flow cytometric analysis 
The procedure for single-colour flow cytometric analysis has been
previously described (Guadagni et al, 1990). Briefly 1 × 106 cells
were washed 3 times with cold Ca2+ and Mg2+-free Dulbecco’s phos-
phate-buffered saline (DPBS) and then stained for 1 h with 1 µ g of
mAb against CD3, CD4, CD8, CD56, CD19, CD11c, CD1a, CD83,
CD86, CD80, CD54, CD58 (all purchased from Becton Dickinson,
San Jose, CA), HLA class I (W6/32) (Scra, Sussex, England), and
MOPC-21 (Cappel/Organon Tecknica Corp. West Chester, PA) in a
volume of 100 µ l of PBS containing 1% bovine serum albumin. The
cells were then washed 3 times with cold DPBS and incubated for
an additional hour in the presence of 1:100 dilution (volume of
100 µ l PBS containing 1% bovine serum albumin) of fluoresceine-
conjugated goat anti-mouse immunoglobulin (Ig) (Kirkengard and
Perry Labs, Gaithersburg, MD, USA). The cells were again washed
3 times with DPBS and resuspended in DPBS at the concentration
of 1 × 106 cells ml–1, and immediately analysed using a Becton
Dickinson FACScan equipped with a blue laser with an excitation of
15 nW at 488 nm. The data were gathered from 10 000 live cells and
used to evaluate results. 
Dual colour flow cytometric analysis 
This procedure closely resembled that used for the single-colour flow
cytometry with the following exceptions. The mAbs used were anti-
CD3 and anti-CD4 fluoresceine conjugate and anti-CD56 and anti-
CD8 phycoerythrin conjugate, anti-IgG1 fluorescein conjugate and
anti-IgG3 phycoerythrin (all purchased from Becton Dickinson, San
Jose, CA). The cells were simultaneously stained for 1 hour and then
washed 3 times, resuspended as above, and immediately analysed
using a Becton Dickinson FACScan equipped, with a blue laser with
an excitation of 15 nW at 488 nm, and the Lysis II program. 
HLA typing 
The HLA phenotyping of the donor PBMC was performed by the
Blood Bank of the Azienda Ospedaliera Senese, Policlinico ‘Le
Scotte’, Siena, Italy using a standard antibody-dependent micro-
cytotoxicity assay and a defined panel of anti-HLA antisera for
HLA class I determinations. 
Statistical consideration 
The differences between means were statistically analysed using
the 2-tailed Student’s  t-test for paired samples and Stat View
statistical software (Abacus Concepts, Berkeley, CA) and the
results were expressed as the mean of 4 determinations derived
from 3 different experiments +/– standard deviation. A P value 
of < 0.05 was considered statistically significant. 
RESULTS 
PTH-rP specific TIL 
A PTR-4 peptide specific CTL line, designated TM-PTR-4, was
generated by the in vitro stimulation of human TIL with PTR-4
peptide-pulsed autologous DC and IL-2. TIL had been isolated
from a metastatic sample taken by a bone biopsy, performed on a
patient with advanced prostate carcinoma enrolled in a clinical
trial of immunotherapy GM-CSF and IL-2 before he received any
immunological treatment. DC were instead, isolated from the
same patient after he had received at least a cycle of treatment with
GM-CSF and IL-2. Immunofluorescence FACS analysis showed
that this patient was HLA-A2.1+, and that the administration of
GM-CSF and IL-2 had indeed increased in his PBMC, the
percentage of cells showing the immunophenotype and the func-
tion of activated bone marrow-derived DC (data from a clinical
trial) (Correale et al, 2001). In order to increase and purify the DC
population to use as APC, patient PBMC, isolated after he had
received the cytokine immunological treatment, were cultured in
medium containing GM-CSF and IL-4 as described above, and
finally used to stimulate the autologous TIL. 
After 4 IVS (8 weeks) this TM-PTR-4 lymphocyte culture was
investigated for immunophenotype expression and cytotoxic activity. 
Progenitor TIL (TM-TIL) were also cultured in presence of IL-
2 and cyclically stimulated with the same irradiated autologous
DC co-cultured in presence of autologous irradiated tumour cells.
After 8 weeks of culture, also these lymphocytes were investigated
for immunophenotype expression and cytotoxic activity. The
immunophenotype study revealed that TM-PTR-4 culture mainly
consisted of CD3+, CD56–, CD5+ (22%), CD45RO+ (45%) cells,
which were prevalently CD4–/CD8+ (65.8%). The TM-TIL had a
similar phenotype with a higher percentage of CD56+ cells (20%),
no CD5+ (2.2%) expression and a much lower percentage of
CD45Ro+ (21%) memory T cells (Table 1). A similar phenotype
was also found in the T cell line, generated by stimulating the
same TIL with peptide-pulsed DC derived from PBMC isolated
before patient treatment with GM-CSF and IL-2 (data not shown).
In this patient no PTH-rP peptide-specific T cell line could be
generated by using PTR-4 pulsed DC to stimulate PBMC isolated
prior cytokine therapy (data not shown). 
As previously described, a CTL line specific for the PTH-rP
peptide was instead generated from PBMC isolated from a HLA-
A2.1+ healthy donor, by means of cyclic stimulation with low-dose
IL-2 and PTR-4 peptide-pulsed autologous DC. DC used as CTL
antigen-presenting cells were generated as described in the
Method section. The CTL line generated in this way, was investi-
gated for immunophenotype expression and cytolytic activity after
4 and 6 IVS (2 and 3 months of culture). Direct double-stain flow
cytometry immunofluorescence showed that the CTL lines
expressed a CD3+ (98%) phenotype with different percentages of
CD56+ (25%), CD4+/CD8– (41.2%), CD4+/CD8+ (15.2%) and
CD4–/CD8+ (37.3%) cells (Table 1). 
% specific lysis = 
observed release (cpm) −  spontaneus release (cpm)
total release (cpm) −  spontaneous release (cpm)
×  1001726 P Correale et al 
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CTL line cytotoxic activity 
6 hour cytotoxic assays be means of 51Cr release technique
revealed that TM-PTR-4 lymphocytes were able to kill CIR-A2
target cells pulsed with PTR-4 peptide or transfected with GC90, a
plasmid engineered to express PTH-rP gene. They also killed the
HLA-A2.1+/PTH-rP+ prostate carcinoma LNCaP cell line (Figure 1).
No CTL mediated lysis was conversely observed against unpulsed
CIR-A2 cells or the cells pulsed with HLA-A2.1 molecule-binding
peptides other than PTR-4, or CIR-A2 transfected with the
plasmid vector (pcDNA3), or against colon cancer SW-1463 cells,
which are HLA-A2.1+ and unable to produce PTH-rP (Figure 1).
Target cell production of PTH-rP and membrane expression of
HLA-A2.1 molecules is shown in Table 2. 
6 hour cytotoxic assays also revealed TM-PTR-4 T-lymphocyte
ability to kill autologous (M-CaP) prostate cancer cells (Figure 1).
Autologous M-CaP prostate cancer cells derived from the same
sample as that from which lymphocytes were isolated, were
cultured in presence of androgens and insulin for 6 weeks before
being used as targets in CTL assays. The cells used as CTL targets
were fibroblast free and had an exponential growth rate (data not
shown). M-CaP cells were considered prostate cancer cells after 
a morphological and immunohistochemical study had been
performed by a pathologist. PSA expression in the epithelial
aggregates was, in fact, demonstrated by immunohistochemistry
as an intense red staining of the cytoplasm that masks nuclei and
cell borders (Figure 2). The M-CaP target cells were also positive
for the expression of HLA-A2.1 (60%), and PTH-rP (25 ng ml–1 ×
106 cells) (Table 2). 
HLA-A2.1 restriction of prostate cancer CTL-mediated
cytolysis 
TM-PTR-4-mediated target cell cytolysis was restricted by HLA-
A2.1 since tumour cell killing was abrogated by the anti-class I
mAb (A2.69) (Figure 1), however prostate cancer cell cytolysis by
the TM-PTR-4 T cell line was not affected by the treatment with a
A2.69 isotype control antibody not reacting with target cells
(Figure 1). 
Bone metastases-derived TIL do not have any cytotoxic
activity against target cells 
Progenitor TIL not stimulated with PTH-rP epitope peptide, were
also investigated for their anti-tumour activity in 6- and 18-hour
cytotoxic assays. The TIL were maintained in culture for 6 and 8
weeks in presence of IL-2, and stimulated every 15 days with
autologous irradiated prostate cancer cells and autologous DC.
This T cell culture (TM-TIL), was not able to lyse LNCaP, SW-
1463, unpulsed or PTR-4 peptide pulsed CIR-A2 targets, as well
as autologous prostate cancer cells (Figure 3). Cytotoxic activity
of patient TIL, in vitro stimulated with peptide-pulsed DC derived
from PBMC isolated prior patient cytokine therapy, was tested
against the same target cells after 4, 6 and 8 in vitro stimulations.
In none of these experiments a PTH-rP as well as a PTH-rP
peptide-specific cytotoxic activity could be demonstrated (data not
shown). The same results were also obtained when peptide-pulsed
autologous (pre or post treatment) DC were used to stimulate in
vitro patient PBMC instead of TIL (data not shown). 
Table 1 Flow cytometric analysis of surface markers on PTH-rP peptide specific CTL lines 
T cell line Surface markers 
CD3+ CD4+/CD8– CD4–/CD8+ CD4+/CD8+ CD56+ CD5+ CD45RO+
TM-TIL 87.2 25.3 69.3 4.5 36 2.2 21 
TM-PTR-4 96.46 28.57 65.81 2.41 3.29 22 45 
aND-PTR-4 98% 41.2% 37.3% 15.2% 25% – 40% 
Results are expressed as percentage of each cell sample reactive with mAb. Routinely 2–4% cells are stained when treated either with no
priming mAb or an isotype related control mAb. aND-PTR-4 represents the CTL line derived from the PBMC of a HLA-A2.1+ healthy donor. 
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Figure 1 6 hour 51Cr release cytotoxic assay. Cytotoxic activity of human TIL
stimulated in vitro with IL-2 and PTH-rP peptide pulsed autologous dendritic
cells against CIR-A2 cells (      ), CIR-A2 pulsed with 25 µ g ml–1 of PTH-rP
(PTR-4) peptide (     ) CIR-A2 cells transfected with pc3-DNA (        ), CIR-
A2 cells transfected with PTH-rP plasmid (GC90) (      ), HLA-A2.1+/PTH-rP–
colon carcinoma SW1463 cells (      ), HLA-A2.1+ /PTH-rP+ prostate
carcinoma LNCaP cells (     ), LNCaP cells in presence of anti-HLA-A2.1
mAb (dilution 1:100) (     ), LNCaP cells in presence of a control isotype
mAb (UPC-10) (      ), PTH-rP+ autologous metastatic prostate cancer
M-CaP cells in presence of UPC-10 (    ), and M-CaP cells in presence of an
anti-HLA-A2.1 (A2,69) mAb (      ). Data shown in the figure are derived from
3 different experiments for each target cell line with similar results. In the
cytotoxic tests the differences between the values from PTH-rP peptide
pulsed- and PTH-rP transfected-CIR-A2 compared with values from unpulsed
CIR-A2 and pcDNA3 trasfected CIR-A2 cells, respectively were found
statistically significant (P < 0.05); the values from LNCaP cells in presence of
A2.69 and SW-1463 cells with the values from LNCaP cells in presence of UPC-
10 and LNCaP cells, respectively were found statistically significant (P < 0.05);
the values from M-CaP cells in presence of UPC-10 and M-CaP cells in
presence of A2.69 respectively, were found statistically significant (P < 0.05) TIL-derived PTH-rP-specific T lymphocytes 1727
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PTH-rP peptide-specific cytotoxic activity of a CTL line
generated from a normal donor 
The PTH-rP and PTH-rP peptide-specific cytotoxic activity of the
CTL line derived from the normal donor was also investigated. In
18-hour cytotoxic assays it was observed that the latter CTL line,
designated normal donor (ND)-PTR-4, was able to kill PTR-4
pulsed or PTH-rP gene transfected CIR-A2 target cells and exerted
a minimal HLA-A2.1 restricted cytotoxic activity against LNCaP
cells (Figure 4). These T lymphocytes were conversely, unable to
kill: the peptide unpulsed CIR-A2 cells; the same targets cells
transfected with the plasmid vector (pcDNA3), or pulsed with the
negative control peptide (CEA-derived) with HLA-A2.1 binding
motifs; and the colon carcinoma, SW-1463 cells (Figure 4). 
In contrast with TM-PTR-4, the PTR-4 specific CTL line (ND-
PTR-4) derived from the normal donor was unable to kill the M-
CaP cells, did not exert any cytotoxic activity in 6 hour 51Cr
release assays (data not shown in figure) and exerted a lower level
of cytotoxic activity against PTR-4 pulsed and GC90 transfected
CIR-A2 and LNCaP target cells (Figures 1 and 4). 
DISCUSSION 
The presence of TIL has been considered an expression of a host
immune reaction against the cancer cells (Vose and Moore, 1985;
Whiteside, 1991). Once activated and expanded in vitro they have
been found to have an effective antitumour activity against autolo-
gous tumour cells (Vose and Moore, 1985; Topalian et al, 1987;
Whiteside, 1991). On the basis of these findings, several clinical
trials have been designed in order to reinfuse autologous ex vivo
expanded TIL (together with IL-2 administration) for the treat-
ment of immunogenic cancers such as malignant melanoma and
Figure 3 6 hour 51Cr release cytotoxic assay. Cytotoxic activity of the
human (TM-TIL), TIL line against CIR-A2 cells (    ), CIR-A2 pulsed with
25 µ g ml–1 of PTH-rP (PTR-4) peptide (   ), HLA-A2.1+/PTH-rP+ prostate
carcinoma LNCaP cells (   ), PTH-rP+ autologous metastatic prostate
cancer M-CaP cells (   ). Data shown in the figure are derived from 3
different experiments for each target cell line with similar results. In the
cytotoxic tests the differences between the values were never found
statistically significant (P > 0.05) 
Figure 2 Expression of prostate-specific antigen (PSA) in metastatic
prostate carcinoma M-CaP cells evaluated by immunohistochemistry 
with labelled monoclonal antibodies. Intense cytoplasmic prostate-specific
antigen (PSA) expression is evident in both metastatic prostate 
carcinoma M-CaP cells (A) and prostate carcinoma cell line (LNCaP) 
used a positive control (B). (Avidin–Streptavidin method; 375× original
magnification) 
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renal cell carcinoma (Topalian et al, 1987; Whiteside, 1991;
Arienti et al, 1993). 
The results of these trials have shown that this therapeutic
approach is well tolerated and has a low level of toxicity, which is
mainly produced by IL-2 administration, but the antitumour effi-
cacy of the protocols is still debated because the studies have been
sporadic and generally based on small patient populations (Arienti
et al, 1993). The role of TIL in the primitive or metastatic
neoplasia in vivo has not yet been defined but, although tumour
antigen-specific cytotoxic activity has been demonstrated in vitro
(Topalian et al, 1987; Arienti et al, 1993; Whiteside and Parmiani,
1994; Pierce et al, 1995), there is clear evidence that for some
reason they are unable to eliminate cancer cells from the site where
they were extracted. 
The results of our study provides demonstration that an
antigen derived CTL epitope (PTR-4) peptide pulsed DC can be
used to generate in vitro a PTH-rP peptide CTL line from
lymphocytes infiltrating a prostate carcinoma bone metastatic
lesion. We have recently, characterized several human CTL lines
specific for PTR-4 and other PTH-rP peptides, generated by in
vitro stimulation of HLA-A2.1+ healthy donor PBMC with low
dose IL-2 and peptide-pulsed autologous DC. These CTL lines
were able to kill in HLA-2.1 restricted manner, CIR-A2 targets
pulsed with the specific peptide used for the CTL line stimula-
tion and HLA-2.1+ prostate (LNCaP) and breast carcinoma cells
(MDA-MB-231) producing PTH-rP. Cold competition assays
also demonstrated the peptide specificity of these CTL lines
since their cytotoxic activity against both LNCaP and MDA-
MB-231 target cells was abrogated by the addition in the cyto-
toxic assays of cold competitors (T2-A2 target cells) previously
pulsed with the specific PTH-rP epitope peptide (Francini et al,
2001). 
In the present study we found that the PTR-4-specific CTL line
generated from the prostate carcinoma patient TIL had similar
immunological features as those observed in the CTL lines derived
from the healthy donor. While the PTH-rP and PTHrP peptide
specificity of these CTL lines was very close, significant differ-
ences were observed in regard to the amount of cytotoxicity and to
the time necessary to kill the target cells. TM-PTR-4 cells were, in
fact, able to lyse the specific target cells in 4–6 hour cytotoxic
assays while the CTL derived from normal donor needed at least
18 hours. In addition, the CTL derived from the normal donor
were unable to kill in vitro the metastatic prostate cancer cells of
the patient (M-CaP). The lack in cytolytic activity of ND-PTR-4
CTL line against M-CaP might be explained considering that the
healthy donor lymphocytes and the tumour cells are not autolo-
gous even though they match for HLA-A2.1 expression; neverthe-
less, it is also possible that the cytotoxic activity of this CTL line is
not strong enough to kill the target cells rapidly. The longer
Table 2 HLA-A2.1 molecule expression and PTH-rP production in lymphocyte target cells 
Target cells HLA-A2.1 expression (%)* PTH-rP production (pg ml–1 × 106 cells)# 
CIR-A2 98.5 (2.2) Not detectable 
CIR-A2 transfected with pcDNA3 97.2 (4.24) Not detectable 
CIR-A2 transfected with GC90  96.6 (3.23) 13.56 (5.6) 
(PTH-rP gene plasmid)
LNCaP 29.8 (3.7) 15.2 (5.5) 
M-CaP 60.1 (2.2) 25.1 (3.5) 
SW1463 75 (3.2) Not detectable 
*HLA-A2.1 expression was evaluated by indirect immunofluorescence using an anti-HLA-A2.1 mAb (A2.69) and a
FICT conjugated goat-anti-mouse. Results are expressed as percentage of fluorescent cells. Marker expression was
considered negative when lower than 4%. Results are expressed as percentage of each cell sample reactive with
mAb. Routinely 2–4% of cells are stained when treated either with no priming mAb or an isotype related control mAb.
#PTH-rP was evaluated by a sandwich immunoradiometric assay (IRMA); values lower than 1.5 pg were considered
negative. *#Numbers in parentheses represent standard deviations (SD). 
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Figure 4 18 hour 51Cr release cytotoxic assay. Cytotoxic activity of human
PBMC stimulated in vitro with IL-2 and PTH-rP peptide-pulsed autologous
dendritic cells against CIR-A2 cells (    ), CIR-A2 pulsed with 25 µ g ml–1
of PTH-rP (PTR-4) peptide (   ), CIR-A2 cells transfected with pc3-DNA 
(   ), CIR-A2 cells transfected with PTH-rP plasmid (GC90) (    ) HLA-
A2.1+/PTH-rP– colon carcinoma SW1463 cells (    ), HLA-A2.1+/PTH-rP+
prostate carcinoma LNCaP cells (   ), LNCaP cells in presence of anti-
HLA-A2.1 mAb (dilution 1:100) (   ), LNCaP cells in presence of a control
isotype mAb (UPC-10) (    ), PTH-rP+ autologous metastatic prostate
cancer M-CaP cells (   ). Data shown in the figure are derived from 3
different experiments for each target cell line with similar results. In the
cytotoxic tests the differences between: the values from PTH-rP peptide-
pulsed-and PTH-rP transfected-CIR-A2 compared with values from unpulsed
CIR-A2 and pcDNA3 trasfected CIR-A2 cells, respectively were found
statistically significant (P < 0.05); the values from LNCaP cells in presence of
A2.69 and SW-1463 cells with the values from LNCaP cells in presence of
UPC-10 and LNCaP cells, respectively were found statistically significant 
(P < 0.05); the values from M-CaP cells with the values from SW-1463 and
CIR-A2 cells were found statistically not significant (P > 0.05) TIL-derived PTH-rP-specific T lymphocytes 1729
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interval of time needed to kill the target cells might give the
chance to the tumour cells to activate their own mechanisms of
defence and eventually to fight back and kill the lymphocytes. At
this purpose several in vitro studies on various tumour cell lines
clearly demonstrated that tumour cells possess different mecha-
nisms of resistance to various cytotoxic immune-effectors (natural
killer (NK), lymphokine activated killer (LAK), TIL, etc) and that
such mechanisms may be modulated in different way with several
drugs or biological response modifiers (Correale et al, 1991, 1992,
1995; Frost et al, 1997; Tagliaferri et al, 1998). To provide a
stronger explanation for this finding further experiments are
presently, in progress to investigate whether ND-PTR-4 (derived
from the normal donor PBMC) and TM-PTR-4 (derived from the
patient TIL) CTL lines utilize the same molecular mechanism to
induce target cell killing (FAS ligand, TNFα , perphorines etc.). 
In this study patient PBMC, in vitro stimulated with peptide-
pulsed autologous DC as well as progenitor TIL, in vitro stimu-
lated with autologous tumour cells and DC, were not able to kill
any of the same targets including the autologous cancer cells.
Although these findings need to be confirmed on a larger number
of patients, we can still hypothesize that we were unable to estab-
lish a PTH-rP-specific CTL line from the PBMC because during
the natural history of the disease, the peripheral blood of this
patient was depleted of PTH-rP peptide-specific precursors which
were gathered and inactivated in the metastatic site where PTH-rP
producing cancer cells are localized. The in vitro stimulation of
TIL with epitope peptides pulsed DC may stimulate such precur-
sors present in high frequency among the lymphocytes infiltrating
the metastatic lesion and eventually rescue their antigen-specific
antitumour activity, which does not seem irremediably altered by
tumour cells as reported in literature (Melero et al, 1997). Peptide-
pulsed DC were chosen to stimulate the TIL in order to induce an
efficient PTH-rP-specific CTL response because of their powerful
antigen-presenting ability. There is evidence indicating that DC
are the most powerful known APC (Grabbe et al, 1995; Bell et al,
1999), and it known that they play a critical role in antigen presen-
tation in vivo and in the induction of antigen-specific CTL
responses. Although tumour cells express antigen peptides 
recognized by CTL, most tumours lack the co-stimulatory mole-
cules necessary for CTL activation (Melero et al, 1997). Antigen-
specific CTL activation and clonal expansion needs in fact,
co-stimulatory surface molecule interactions between effector-
precursors (CD28) and antigen peptide-presenting cells
(CD80/B7.1; CD86/B7.2), such as DC, activated B lymphocytes,
and monocytes (Grabbe et al, 1995; Melero et al, 1997; Bell et al,
1999). Unlike other member of the APC family, DC are capable of
inducing primary immune responses by activating naive T cells
(Markowicz and Engleman, 1990; Grabbe et al, 1995; Bell et al,
1999; Liuykx-de Bakker et al, 1999). The DC used in this study
were derived from a prostate cancer patient enrolled in a clinical
trial after he had received GM-CSF and IL-2. The biological
results of that study, which tested the effects of a sequential combi-
nation of the 2 cytokine, showed that the treatment affects the
immunocompetence of cancer patients (Correale et al, 2001), a
finding that may have a direct clinical application as the cell
context in which an antigen peptide is presented to the immune
system is critical for the induction of an efficient antigen-specific
immune response (Panelli and Marincola, 1998; Rosenberg et al,
1998). The study showed that the administration of human recom-
binant (hr) GM-CSF and hr IL-2 increases the percentage of
PBMC-expressing bone marrow-derived DC markers and also
promotes DC maturation and functions, as suggested by the
finding of a higher expression of CD83, CD80 and CD86 on
PBMC populations gated as DC (Correale et al, 2001). 
In order to estimate the DC enrichment, patient PBMC and the
derivative cultures were examined for the expression of CD1a,
HLA-I, HLA-DR, CD11c, CD86, CD83, and CD80, all which are
known to be markers highly expressed by activated DC (Bell et al,
1999) and to be involved in T cell co-stimulation and activation. 
This study also demonstrated that the DC derived from a patient
with prostate cancer who had received GM-CSF and IL-2 are able
to stimulate tumour infiltrating initiating and can induce an
antigen-specific immune reaction with antitumour activity. PTH-
rP peptide-pulsed DC derived from pretreatment patient PBMC
were not able to generate any PTH-rP-specific CTL response in
autologous TIL. This result suggests that the cytokine treatment
induced functional modification in circulating DC that results 
in an increased antigen-presenting ability. This hypothesis is
supported by the recent finding that GM-CSF and IL-2 adminis-
tered in cancer patients enhance the antigen-presenting ability of
their PBMC increasing their proliferative response to influenza
antigens (Correale et al, 2001). 
The results of the present study could have an immediate clin-
ical application as PTH-rP is over-expressed in 90% of primary
prostate carcinoma and 90% of epithelial malignancies derived
from bone metastases (Guise, 1997). A number of authors have
reported that PTH-rP mediates the interaction of tumour cells with
normal osteoclast cells, which ultimately promote tumour cell
survival and growth in the bone, and the same authors consider
PTH-rP a molecular structure that is indispensable for the forma-
tion of bone metastases from prostate, breast and lung carcinoma
(Guise, 1997). Recognition by cytotoxic T-cell lines suggests that
PTR-4 peptide-based vaccine therapy and PTR-4-specific TIL
adoptive reinfusions may be potential candidates for use in the
treatment of prostate carcinoma bone metastases. 
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